carbamazepine has been researched along with chronic COVID syndrome in 1 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We carried out a systematic search for publications in English and Russian on the safety and efficacy of CMZ in depressive disorders of different etiologies in the PubMed, Web of Science, Springer, Clinical Keys, Google Schooler, E-Library databases using keywords and combined word searches (carbamazepine, COVID-19, depression, epilepsy, post-COVID-syndrome) for the period from January 01,2020 to June 10, 2022." | 9.22 | Possible Clinical and Pharmacogenetic Predictors of the Efficacy and Safety of Carbamazepine in Post-COVID-19 Depression. ( Cumming, P; Davydkin, I; Fedyashov, I; Gayduk, A; Nasyrova, R; Shnayder, N; Smirnova, D; Strelnik, A; Vaiman, E, 2022) |
| "We carried out a systematic search for publications in English and Russian on the safety and efficacy of CMZ in depressive disorders of different etiologies in the PubMed, Web of Science, Springer, Clinical Keys, Google Schooler, E-Library databases using keywords and combined word searches (carbamazepine, COVID-19, depression, epilepsy, post-COVID-syndrome) for the period from January 01,2020 to June 10, 2022." | 5.22 | Possible Clinical and Pharmacogenetic Predictors of the Efficacy and Safety of Carbamazepine in Post-COVID-19 Depression. ( Cumming, P; Davydkin, I; Fedyashov, I; Gayduk, A; Nasyrova, R; Shnayder, N; Smirnova, D; Strelnik, A; Vaiman, E, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vaiman, E | 1 |
| Gayduk, A | 1 |
| Strelnik, A | 1 |
| Smirnova, D | 1 |
| Davydkin, I | 1 |
| Fedyashov, I | 1 |
| Cumming, P | 1 |
| Shnayder, N | 1 |
| Nasyrova, R | 1 |
1 review available for carbamazepine and chronic COVID syndrome
| Article | Year |
|---|---|
Possible Clinical and Pharmacogenetic Predictors of the Efficacy and Safety of Carbamazepine in Post-COVID-19 Depression.
Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Carbamazepine; COVID-19; COVID-19 Drug Trea | 2022 |